Dr. Alexander James Caten, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 750 N Syringa St Ste 203a, Post Falls, ID 83854 Phone: 208-262-2717 Fax: 208-262-2719 |
Dr. Brandy Marie Tacia, DO Otolaryngology - Facial Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 750 N Syringa St Ste 203a, Post Falls, ID 83854 Phone: 208-262-2717 Fax: 208-262-2719 |
Dr. Chad D Mccormick, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 849 N Syringa St, Post Falls, ID 83854 Phone: 208-777-1320 Fax: 208-777-1322 |
Dr. Michael Erik Gilbert, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 849 N Syringa St, Post Falls, ID 83854 Phone: 208-777-1320 Fax: 208-777-1322 |
News Archive
CompuGroup Medical US, developer of the market-leading LabDAQ Laboratory Information System (LIS), is proud to announce the release of LabNexus, a new software solution to assist hospital and reference labs with their outreach programs. LabNexus allows laboratories to send orders and review results, all within a completely cloud-based system.
A compelling clinical article published online in the March 2011 issue of Journal of Neurosurgery: Pediatrics, entitled Helmet Use Reduces Skull Fractures in Skiers and Snowboarders Admitted to the Hospital discusses skull fractures incurred by young skiers and snowboarders and the role helmets play in reducing these head injuries.
To provide increased value to healthcare facilities, Toshiba America Medical Systems, Inc. expands its Assurance Program to offer reconditioned Toshiba ultrasound systems. Assurance ultrasound products include Aplio XG, Aplio MX, Aplio Artida, Viamo, and Xario XG.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that Ryo Kubota, M.D., Ph.D., Acucela's chairman, president and chief executive officer, has been invited to participate in Retina International's annual Scientific & Medical Advisory Board meeting being held in Fort Lauderdale, Florida on May 3, 2010.
Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.
› Verified 2 days ago